Summary

Delirium Market Research Report Forecast till 2030

Market Overview
The Delirium Market is anticipated to register a CAGR of 5.84% during the review period. Developing maturing populace, further developed distinguishing proof and finding, and mechanical headways are driving the market development.
The maturing populace is a critical driver of the delirium market. As the worldwide populace encounters a segment shift towards more seasoned grown-ups, the pervasiveness of delirium increments. More seasoned people are more powerless to delirium because of variables, for example, hidden medical issue, mental debilitations, polypharmacy, and hospitalization. The physiological changes related with maturing, like modifications in synapses and diminished mental save, additionally add to the weakness to delirium. The maturing populace's effect on the delirium market is complex. Right off the bat, it prompts a more prominent number of delirium cases, provoking a higher interest for indicative instruments, mediations, and the executives’ procedures.
Furthermore, the maturing populace impacts innovative work endeavors zeroed in on figuring out the fundamental systems of delirium and creating age-explicit mediations. It additionally highlights the significance of interdisciplinary joint effort and preparing to furnish medical care experts with the information and abilities fundamental for successful delirium the board in more seasoned grown-ups. In general, the developing maturing populace is a main thrust behind the extension and progression of the delirium market.
Market Segmentation
Based on kind, the Delirium Market is divided into three segments: Hyperactive, Hypoactive, and Mixed.
The segmentation of the delirium market is predicated on diagnosis and therapy, which comprises both diagnosis and treatment.
The market is divided into hospitals, specialty care, and research centers based on the end-user.
The North American Delirium market addressed the greatest market share in 2022 considering developing people and a rising in continuous disorders, there is an extended knowledge of delirium as a fundamental piece of patient thought. The region's well established clinical benefits establishment and high-level clinical assessment add to the improvement of expressive and medicinal progressions in delirium the board.
Europe Delirium market should address the second-greatest market share in light of the extraordinary prosperity courses of action and example towards organizing prosperity organizations, including directing.
The Asia-Pacific clinical consideration directing market should create at the speediest rate from 2023 to 2030. This is a direct result of the rising spending in clinical benefits, quickly creating clinical consideration establishment, creating care with respect to Delirium, and creating people in the region.
The Rest of the World integrates the Middle East, Africa, and Latin America. The chief variables affecting the advancement of Delirium are in the Middle East and Africa.
Key Market Players
The key market players are Mylan N.V (US), Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Zydus Group (India), Pfizer (India), Teva Pharmaceutical Industries Ltd (Israel), and Novartis AG (Switzerland).

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. EXECUTIVE’S HANDBOOK
1.1. THE TOP PERFORMING SEGMENTS
1.2. KEY TRENDS SUMMARIZED
1.3. PRICING OUTLOOK
1.4. STRATEGIC INSIGHTS
1.5. WHO ARE THE KEY PLAYERS IN THE MARKET?
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2. MARKET INTRODUCTION
2.1. DEFINITION
2.2. REPORT SEGMENTATION & SCOPE
2.3. REGIONAL & COUNTRY LEVEL COVERAGE
2.4. WHY YOU NEED THIS REPORT?
3. RESEARCH METHODOLOGY
3.1. RESEARCH PROCESS
3.2. SECONDARY RESEARCH
3.2.1. DATA MINING & CONDENSATION
3.2.2. SOURCES (ASSOCIATIONS, ORGANIZATIONS, MAGAZINES, PAID DATABASES)
3.3. PRIMARY RESEARCH
3.3.1. SAMPLE SIZE (DEMAND-SUPPLY, COMPANY TYPE, DESIGNATIONS, REGION)
3.3.2. SOURCES
3.4. FACTORIAL ANALYSIS & APPROACH SETTING
3.5. ESTIMATION & FORECAST MODELS
3.6. PRICING BASKETS
3.7. ANALYST HOURS & TEAM
SECTION III: QUALITATIVE ANALYSIS
4. MARKET DYNAMICS
4.1. INTRODUCTION
4.2. GROWTH PARAMETERS MAPPED - DRIVERS
4.2.1. GROWING AGING POPULATION
4.2.2. IMPROVED IDENTIFICATION AND DIAGNOSIS
4.2.3. INCREASING DEMAND FOR TECHNOLOGICALLY ADVANCED TREATMENT
4.3. WHAT ARE THE CHALLENGES FACED BY INDUSTRY PARTICIPANTS?
4.3.1. HIGH COST OF TREATMENT
4.3.2. THREAT TO DATA SECURITY &STRICT REGULATORY COMPLIANCE
4.4. OPPORTUNITIES
4.4.1. COLLABORATION WITH PHARMACEUTICAL COMPANIES AND ACADEMIC INSTITUTIONS
4.4.2. OPPORTUNITY 2
4.4.3. OPPORTUNITY 3
5. MARKET FACTOR ANALYSIS
5.1. VALUE CHAIN ANALYSIS
5.1.1. R&D AND DESIGNING
5.1.2. MANUFACTURING
5.1.3. DISTRIBUTION & SALES
5.1.4. POST SALES SERVICES
5.2. PORTER’S FIVE FORCES MODEL
5.2.1. BARGAINING POWER OF SUPPLIERS
5.2.2. BARGAINING POWER OF BUYERS
5.2.3. THREAT OF NEW ENTRANTS
5.2.4. THREAT OF SUBSTITUTES
5.2.5. INTENSITY OF RIVALRY
5.3. COVID-19 IMPACT ANALYSIS
5.3.1. IMPACT ON R&D
5.3.2. IMPACT ON PRICING
5.3.3. IMPACT ON REGIONS
SECTION IV: QUANTITATIVE ANALYSIS
6. GLOBAL DELIRIUM MARKET, BY TYPE (USD MILLION)
6.1. INTRODUCTION
6.2. HYPERACTIVE
6.2.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY HYPERACTIVE, 2019-2030
6.3. HYPOACTIVE
6.3.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY HYPOACTIVE, 2019-2030
6.4. MIXED
6.4.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY MIXED, 2019-2030
7. GLOBAL DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT (USD MILLION)
7.1. INTRODUCTION
7.2. DIAGNOSIS
7.2.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS, 2019-2030
7.2.2. LABORATORY TESTS
7.2.3. PHYSICAL EXAMINATION
7.2.4. IMAGING TEST
7.3. TREATMENT
7.3.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TREATMENT, 2019-2030
7.3.2. ANTIPSYCHOTICS
7.3.3. SUPPORTIVE CARE
8. GLOBAL DELIRIUM MARKET, BY END USER (USD MILLION)
8.1. INTRODUCTION
8.2. HOSPITALS
8.2.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY HOSPITALS, 2019-2030
8.3. SPECIALITY CARE
8.3.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY SPECIALITY CARE, 2019-2030
8.4. RESEARCH CENTERS
8.4.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY RESEARCH CENTERS, 2019-2030
9. GLOBAL DELIRIUM MARKET, BY REGION (USD MILLION)
9.1. INTRODUCTION
9.2. NORTH AMERICA
9.2.1. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY COUNTRY, 2019-2030
9.2.2. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.2.3. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.2.4. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.2.5. US
9.2.6. US DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.2.7. US DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.2.7.1. US DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.2.8. CANADA
9.2.8.1. CANADA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.2.8.2. CANADA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.2.8.3. CANADA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.2.9. MEXICO
9.2.9.1. MEXICO DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.2.9.2. MEXICO DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.2.9.3. MEXICO DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.3. EUROPE
9.3.1.1. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY COUNTRY, 2019-2030
9.3.1.2. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.3.1.3. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.3.1.4. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.3.2. GERMANY
9.3.2.1. GERMANY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.3.2.2. GERMANY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.3.2.3. GERMANY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.3.3. FRANCE
9.3.3.1. FRANCE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.3.3.2. FRANCE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.3.3.3. FRANCE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.3.4. UK
9.3.4.1. UK DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.3.4.2. UK DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.3.4.3. UK DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.3.5. SPAIN
9.3.5.1. SPAIN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.3.5.2. SPAIN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.3.5.3. SPAIN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.3.6. ITALY
9.3.6.1. ITALY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.3.6.2. ITALY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.3.6.3. ITALY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.3.7. REST OF EUROPE
9.3.7.1. REST OF EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.3.7.2. REST OF EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.3.7.3. REST OF EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.4. ASIA-PACIFIC
9.4.1. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY COUNTRY, 2019-2030
9.4.2. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.4.3. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.4.4. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.4.5. CHINA
9.4.5.1. CHINA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.4.5.2. CHINA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.4.5.3. CHINA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.4.6. INDIA
9.4.6.1. INDIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.4.6.2. INDIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.4.6.3. INDIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.4.7. JAPAN
9.4.7.1. JAPAN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.4.7.2. JAPAN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.4.7.3. JAPAN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.4.8. SOUTH KOREA
9.4.8.1. SOUTH KOREA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.4.8.2. SOUTH KOREA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.4.8.3. SOUTH KOREA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.4.9. AUSTRALIA
9.4.9.1. AUSTRALIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.4.9.2. AUSTRALIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.4.9.3. AUSTRALIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.4.10. REST OF ASIA-PACIFIC
9.4.10.1. REST OF ASIA-PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.4.10.2. REST OF ASIA-PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.4.10.3. REST OF ASIA-PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.5. REST OF THE WORLD
9.5.1. MIDDLE EAST & AFRICA
9.5.1.1. MIDDLE EAST AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.5.1.2. MIDDLE EAST AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.5.1.3. MIDDLE EAST AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
9.5.2. LATIN AMERICA
9.5.2.1. LATIN AMERICA AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030
9.5.2.2. LATIN AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030
9.5.2.3. LATIN AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030
SECTION V: COMPETITIVE ANALYSIS
10. COMPETITIVE LANDSCAPE
10.1. INTRODUCTION
10.2. COMPETITION DASHBOARD
10.3. COMPANY MARKET SHARE ANALYSIS, 2019-23 (%)
10.4. WHO ARE THE MARKET DISRUPTORS & INNOVATORS?
10.5. WHAT STRATEGIES ARE BEING ADOPTED BY MARKET LEADERS?
10.6. COMPETITIVE BENCHMARKING
10.7. THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL DELIRIUM MARKET
10.8. LIST OF KEY PLAYERS, BY REGION
10.9. PUBLIC PLAYERS STOCK SUMMARY
10.10. COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
10.11. KEY DEVELOPMENTS & GROWTH STRATEGIES
10.11.1. NEW TYPE LAUNCH/SERVICE DEPLOYMENT
10.11.2. MERGER & ACQUISITION
10.11.3. JOINT VENTURES
11. COMPANY PROFILES
11.1. OTSUKA PHARMACEUTICAL CO., LTD
11.1.1. COMPANY OVERVIEW
11.1.2. FINANCIAL OVERVIEW
11.1.3. PRODUCT OFFERED
11.1.4. KEY DEVELOPMENTS
11.1.5. SWOT ANALYSIS
11.1.6. KEY STRATEGIES
11.2. MYLAN N.V
11.2.1. COMPANY OVERVIEW
11.2.2. FINANCIAL OVERVIEW
11.2.3. PRODUCT OFFERED
11.2.4. KEY DEVELOPMENTS
11.2.5. SWOT ANALYSIS
11.2.6. KEY STRATEGIES
11.3. TEVA PHARMACEUTICAL INDUSTRIES LTD
11.3.1. COMPANY OVERVIEW
11.3.2. FINANCIAL OVERVIEW
11.3.3. PRODUCT OFFERED
11.3.4. KEY DEVELOPMENTS
11.3.5. SWOT ANALYSIS
11.3.6. KEY STRATEGIES
11.4. ZYDUS GROUP
11.4.1. COMPANY OVERVIEW
11.4.2. FINANCIAL OVERVIEW
11.4.3. PRODUCT OFFERED
11.4.4. KEY DEVELOPMENTS
11.4.5. SWOT ANALYSIS
11.4.6. KEY STRATEGIES
11.5. GLENMARK PHARMACEUTICALS LTD
11.5.1. COMPANY OVERVIEW
11.5.2. FINANCIAL OVERVIEW
11.5.3. PRODUCT OFFERED
11.5.4. KEY DEVELOPMENTS
11.5.5. SWOT ANALYSIS
11.5.6. KEY STRATEGIES
11.6. PFIZER
11.6.1. COMPANY OVERVIEW
11.6.2. FINANCIAL OVERVIEW
11.6.3. PRODUCT OFFERED
11.6.4. KEY DEVELOPMENTS
11.6.5. SWOT ANALYSIS
11.6.6. KEY STRATEGIES
11.7. MYLAN N.V
11.7.1. COMPANY OVERVIEW
11.7.2. FINANCIAL OVERVIEW
11.7.3. PRODUCT OFFERED
11.7.4. KEY DEVELOPMENTS
11.7.5. SWOT ANALYSIS
11.7.6. KEY STRATEGIES
11.8. TEVA PHARMACEUTICAL INDUSTRIES LTD
11.8.1. COMPANY OVERVIEW
11.8.2. FINANCIAL OVERVIEW
11.8.3. PRODUCT OFFERED
11.8.4. KEY DEVELOPMENTS
11.8.5. SWOT ANALYSIS
11.8.6. KEY STRATEGIES
11.9. GLENMARK PHARMACEUTICALS LTD
11.9.1. COMPANY OVERVIEW
11.9.2. FINANCIAL OVERVIEW
11.9.3. PRODUCT OFFERED
11.9.4. KEY DEVELOPMENTS
11.9.5. SWOT ANALYSIS
11.9.6. KEY STRATEGIES
11.10. NOVARTIS AG
11.10.1. COMPANY OVERVIEW
11.10.2. FINANCIAL OVERVIEW
11.10.3. PRODUCT OFFERED
11.10.4. KEY DEVELOPMENTS
11.10.5. SWOT ANALYSIS
11.10.6. KEY STRATEGIES
12. RECOMMENDATIONS & EXPERT INSIGHTS
12.1. WHAT IS THE SHORT-TERM VS LONG-TERM OUTLOOK FOR DELIRIUM MARKET?
12.2. WHO ARE THE PLAYERS TO LOOK OUT FOR?
12.3. WHAT WILL THE PRODUCT MIX LOOK IN COMING YEARS?
13. MRFR OFFERINGS & TEAM
13.1. CITATIONS & MEDIA
13.2. OUR REGIONAL REPRESENTATIVES
13.3. RELATED REPORTS
13.4. OUR DOMAIN COVERAGE